Literature DB >> 19142114

Sources of unreliability in depression ratings.

Kenneth A Kobak1, Brianne Brown, Ian Sharp, Hollie Levy-Mack, Kurrie Wells, Felice Ockun, Felice Okum, Janet B W Williams.   

Abstract

BACKGROUND: Good interrater reliability is essential to minimize error variance and improve study power. Reasons why raters differ in scoring the same patient include information variance (different information obtained because of asking different questions), observation variance (the same information is obtained, but raters differ in what they notice and remember), interpretation variance (differences in the significance attached to what is observed), criterion variance (different criteria used to score items), and subject variance (true differences in the subject). We videotaped and transcribed 30 pairs of interviews to examine the most common sources of rater unreliability.
METHOD: Thirty patients who experienced depression were independently interviewed by 2 different raters on the same day. Raters provided rationales for their scoring, and independent assessors reviewed the rationales, the interview transcripts, and the videotapes to code the main reason for each discrepancy. One third of the interviews were conducted by raters who had not administered the Hamilton Depression Rating Scale before; one third, by raters who were experienced but not calibrated; and one third, by experienced and calibrated raters.
RESULTS: Experienced and calibrated raters had the highest interrater reliability (intraclass correlation [ICC]; r = 0.93) followed by inexperienced raters (r = 0.77) and experienced but uncalibrated raters (r = 0.55). The most common reason for disagreement was interpretation variance (39%), followed by information variance (30%), criterion variance (27%), and observation variance (4%). Experienced and calibrated raters had significantly less criterion variance than the other cohorts (P = 0.001).
CONCLUSIONS: Reasons for disagreement varied by level of experience and calibration. Experienced and uncalibrated raters should focus on establishing common conventions, whereas experienced and calibrated raters should focus on fine tuning judgment calls on different thresholds of symptoms. Calibration training seems to improve reliability over experience alone. Experienced raters without cohort calibration had lower reliability than inexperienced raters.

Entities:  

Mesh:

Year:  2009        PMID: 19142114     DOI: 10.1097/JCP.0b013e318192e4d7

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

1.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

2.  Predictive Value of Baseline Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) Assessments for Identifying Risk of Prospective Reports of Suicidal Behavior During Research Participation.

Authors:  John H Greist; James C Mundt; Chad J Gwaltney; James W Jefferson; Kelly Posner
Journal:  Innov Clin Neurosci       Date:  2014-09

3.  A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites.

Authors:  Boadie W Dunlop; Michael E Thase; Chuan-Chuan Wun; Rana Fayyad; Christine J Guico-Pabia; Jeff Musgnung; Philip T Ninan
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

4.  Feasibility of Virtual Research Visits in Fox Trial Finder.

Authors:  E Ray Dorsey; Joseph D Wagner; Michael T Bull; Ashley Rizzieri; Justin Grischkan; Meredith A Achey; Todd Sherer; Sohini Chowdhury; Claire Meunier; Lily Cappelletti; Charlotte Rocker; Irene H Richard; Heidi Schwarz; Gail Kang; Stacy H Ahmad; Rachel A Biemiller; Kevin M Biglan
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

5.  The computerized adaptive diagnostic test for major depressive disorder (CAD-MDD): a screening tool for depression.

Authors:  Robert D Gibbons; Giles Hooker; Matthew D Finkelman; David J Weiss; Paul A Pilkonis; Ellen Frank; Tara Moore; David J Kupfer
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

Review 6.  Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

Authors:  Larry Alphs; Fabrizio Benedetti; W Wolfgang Fleischhacker; John M Kane
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-05       Impact factor: 5.176

Review 7.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

8.  Use of a structured functional evaluation process for independent medical evaluations of claimants presenting with disabling mental illness: rationale and design for a multi-center reliability study.

Authors:  Monica Bachmann; Wout de Boer; Stefan Schandelmaier; Andrea Leibold; Renato Marelli; Joerg Jeger; Ulrike Hoffmann-Richter; Ralph Mager; Heinz Schaad; Thomas Zumbrunn; Nicole Vogel; Oskar Bänziger; Jason W Busse; Katrin Fischer; Regina Kunz
Journal:  BMC Psychiatry       Date:  2016-07-29       Impact factor: 3.630

Review 9.  Inter-rater agreement in evaluation of disability: systematic review of reproducibility studies.

Authors:  Jürgen Barth; Wout E L de Boer; Jason W Busse; Jan L Hoving; Sarah Kedzia; Rachel Couban; Katrin Fischer; David Y von Allmen; Jerry Spanjer; Regina Kunz
Journal:  BMJ       Date:  2017-01-25

10.  Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability.

Authors:  C M R Hendriks; L A Saketkoo; M D P Elfferich; J De Vries; P A H M Wijnen; M Drent
Journal:  Lung       Date:  2019-05-17       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.